A Study of rSIFN-co in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase I study of rSIFN-co (3 times a week via subcutaneous
injection for 21 days, with 1 week of washout per cycle).
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Huiyang Life Science and Technology Corporation